Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Goodstal, S."'
Autor:
Gaudio, E., Tarantelli, C., Kwee, I., Barassi, C., Bernasconi, E., Rinaldi, A., Ponzoni, M., Cascione, L., Targa, A., Stathis, A., Goodstal, S., Zucca, E., Bertoni, F. *
Publikováno v:
In Annals of Oncology June 2016 27(6):1123-1128
Autor:
Antonova, Lilia1 (AUTHOR) lantonova@ohri.ca, Paramanthan, Piriya2 (AUTHOR), Falls, Theresa3 (AUTHOR), Wedge, Marie-Eve3 (AUTHOR), Mayer, Justin3 (AUTHOR), Sekhon, Harman S.4 (AUTHOR) hsekhon@toh.on.ca, McPherson, John5 (AUTHOR), Denroche, Robert E.5 (AUTHOR), Gallinger, Steven5 (AUTHOR), Bell, John Cameron3 (AUTHOR), Ilkow, Carolina S.3 (AUTHOR), Chatterjee, Avijit2 (AUTHOR)
Publikováno v:
Cancers. Aug2024, Vol. 16 Issue 15, p2721. 18p.
Autor:
Lebbé C; Dermatology and CIC, AP-HP, Saint Louis Hospital, and Université de Paris, INSERM U976, Paris, France. celeste.lebbe@aphp.fr., Italiano A; Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France.; University of Bordeaux, Bordeaux, France., Houédé N; Medical Oncology, Institut de Cancérologie du Gard, CHU Caremeau, Nîmes, France., Awada A; Oncology Médicine Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Aftimos P; Oncology Médicine Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Lesimple T; Medical Oncology Department, Comprehensive Cancer Center Eugène Marquis, Rennes, France., Dinulescu M; Department of Dermatology, Rennes University Hospital, Rennes, France., Schellens JHM; Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands., Leijen S; Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Rottey S; Department of Medical Oncology, Ghent University Hospital and Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium., Kruse V; Department of Medical Oncology, Ghent University Hospital and Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium., Kefford R; Crown Princess Mary Cancer Centre Westmead Hospital, Faculty of Medicine and Health Sciences, Macquarie University, and Melanoma Institute Australia, Sydney, NSW, Australia., Raymond E; Medical Oncology, Groupe Hospitalier Paris St Joseph, Paris, France., Faivre S; Medical Oncology, Beaujon University Hospital, Clichy, France., Pages C; Dermatology and CIC, AP-HP, Saint Louis Hospital, and Université de Paris, INSERM U976, Paris, France., Gomez-Roca C; Clinical Research Unit, Institut Universitaire du Cancer, Oncopole, Toulouse, France., Schueler A; Global Biostatistics and Epidemiology, EMD Serono Research and Development Institute, Inc. (an affiliate of Merck KGaA, Darmstadt, Germany), Billerica, MA, USA., Goodstal S; Translational Research, EMD Serono Research and Development Institute, Inc. (an affiliate of Merck KGaA, Darmstadt, Germany), Billerica, MA, USA., Massimini G; Early Clinical Oncology Global Clinical Development Biopharma, Merck KGaA, Darmstadt, Germany., Delord JP; Clinical Research Unit, Institut Universitaire du Cancer, Oncopole, Toulouse, France.
Publikováno v:
Targeted oncology [Target Oncol] 2021 Jan; Vol. 16 (1), pp. 47-57.
Autor:
Lliberos, Carolina1,2 (AUTHOR) carolina.lliberos@monash.edu, Richardson, Gary2 (AUTHOR) gary.richardson@cabrini.com.au, Papa, Antonella1 (AUTHOR) gary.richardson@cabrini.com.au
Publikováno v:
Biomolecules (2218-273X). May2024, Vol. 14 Issue 5, p585. 24p.
Autor:
de Weger VA; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. v.deweger@gmail.com., de Jonge M; Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands., Langenberg MHG; UMC Utrecht Cancer Center, Utrecht, The Netherlands., Schellens JHM; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands., Lolkema M; Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.; UMC Utrecht Cancer Center, Utrecht, The Netherlands., Varga A; Gustave Roussy, INSERM 1030, F-94805, Villejuif, France., Demers B; Sanofi Oncology, Vitry-sur-Seine, France., Thomas K; Sanofi Oncology, Cambridge, USA., Hsu K; Sanofi Oncology, Cambridge, USA., Tuffal G; Sanofi R&D, Montpellier, France., Goodstal S; EMD Serono Research & Development Institute, Inc., Billerica, USA., Macé S; Sanofi Oncology, Vitry-sur-Seine, France., Deutsch E; Gustave Roussy, INSERM 1030, F-94805, Villejuif, France.; University Paris-Sud, University Paris-Saclay, F-94270, Le Kremlin-Bicêtre, France.
Publikováno v:
British journal of cancer [Br J Cancer] 2019 Feb; Vol. 120 (3), pp. 286-293. Date of Electronic Publication: 2018 Dec 26.
Autor:
Vena F; Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6DD, UK., Jia R; Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6DD, UK., Esfandiari A; Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6DD, UK., Garcia-Gomez JJ; Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6DD, UK., Rodriguez-Justo M; Department of Research Pathology, UCL Cancer Institute, London EC1M6BQ, UK., Ma J; EMD Serono Research and Development Institute, Billerica 01821, MA, USA., Syed S; EMD Serono Research and Development Institute, Billerica 01821, MA, USA., Crowley L; EMD Serono Research and Development Institute, Billerica 01821, MA, USA., Elenbaas B; EMD Serono Research and Development Institute, Billerica 01821, MA, USA., Goodstal S; EMD Serono Research and Development Institute, Billerica 01821, MA, USA., Hartley JA; Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6DD, UK., Hochhauser D; Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6DD, UK.
Publikováno v:
Oncotarget [Oncotarget] 2018 Jan 22; Vol. 9 (14), pp. 11592-11603. Date of Electronic Publication: 2018 Jan 22 (Print Publication: 2018).
Autor:
Godfrey, Laura K.1,2 (AUTHOR), Forster, Jan2,3 (AUTHOR), Liffers, Sven-Thorsten1,2 (AUTHOR), Schröder, Christopher3 (AUTHOR), Köster, Johannes4 (AUTHOR), Henschel, Leonie5 (AUTHOR), Ludwig, Kerstin U.5 (AUTHOR), Lähnemann, David2 (AUTHOR), Trajkovic-Arsic, Marija1,2 (AUTHOR), Behrens, Diana6 (AUTHOR), Scarpa, Aldo7,8 (AUTHOR), Lawlor, Rita T.8 (AUTHOR), Witzke, Kathrin E.9 (AUTHOR), Sitek, Barbara9,10 (AUTHOR), Johnsen, Steven A.11,12 (AUTHOR), Rahmann, Sven13 (AUTHOR), Horsthemke, Bernhard14 (AUTHOR), Zeschnigk, Michael2,14 (AUTHOR), Siveke, Jens T.1,2,15 (AUTHOR) jens.siveke@uk-essen.de
Publikováno v:
Clinical Epigenetics. 1/16/2024, Vol. 16 Issue 1, p1-22. 22p.
Autor:
Vena F; Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, University College London, London, United Kingdom., Li Causi E; Barts Cancer Institute, University of London, London, United Kingdom., Rodriguez-Justo M; Department of Research Pathology, UCL Cancer Institute, London, United Kingdom., Goodstal S; EMD Serono Research and Development Institute, Billerica, Massachusetts., Hagemann T; Barts Cancer Institute, University of London, London, United Kingdom., Hartley JA; Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, University College London, London, United Kingdom., Hochhauser D; Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, University College London, London, United Kingdom. d.hochhauser@ucl.ac.uk.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2015 Dec 15; Vol. 21 (24), pp. 5563-77. Date of Electronic Publication: 2015 Jul 30.
Autor:
Lee J; 1. Section of Translational Breast Cancer Research and Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology - Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA;, Galloway R; 2. Department of Bioinformatics and Computational Biology - Unit 1410, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA;, Grandjean G; 3. Department of Experimental Therapeutics - Unit 1950, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA;, Jacob J; 3. Department of Experimental Therapeutics - Unit 1950, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA;, Humphries J; 1. Section of Translational Breast Cancer Research and Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology - Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA;, Bartholomeusz C; 1. Section of Translational Breast Cancer Research and Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology - Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA;, Goodstal S; 4. EMD Serono Research & Development Institute, Inc., 45A Middlesex Turnpike, Billerica, MA, 01821, USA., Lim B; 1. Section of Translational Breast Cancer Research and Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology - Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA;, Bartholomeusz G; 3. Department of Experimental Therapeutics - Unit 1950, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA;, Ueno NT; 1. Section of Translational Breast Cancer Research and Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology - Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA;, Rao A; 2. Department of Bioinformatics and Computational Biology - Unit 1410, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA;
Publikováno v:
Journal of Cancer [J Cancer] 2015 Oct 28; Vol. 6 (12), pp. 1306-19. Date of Electronic Publication: 2015 Oct 28 (Print Publication: 2015).
Autor:
Soung, Young-Hwa1 (AUTHOR) younghwa.song@stonybrookmedicine.edu, Chung, Jun1 (AUTHOR) jun.chung@stonybrookmedicine.edu
Publikováno v:
Biomolecules (2218-273X). Oct2023, Vol. 13 Issue 10, p1480. 18p.